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Purification and characterization of 
pre-mRNA splicing factor SF2 from 
HeLa cells 
Adrian R. Krainer, ~ Greg C. Conway,  and Diane Kozak 
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 USA 
SF2, an activity necessary for 5' splice site cleavage and lariat formation during pre-mRNA splicing in v/tro, has 
been purified to near homogeneity from HeLa cells. The purest fraction contains only two related polypeptides 
of 33 kD. This fraction is sufficient o complement an SI00 fraction, which contains the remaining splicing 
factors, to splice several pre-mRNAs. The optimal amount of SF2 required for efficient splicing depends on the 
pre-mRNA substrate. SF2 is distinct from the hnRNP A1 and U1 snRNP A polypeptides, which are similar in 
size. Endogenous hnRNA copurifies with SF2, but this activity does not appear to have an essential RNA 
component. SF2 appears to be necessary for the assembly or stabilization of the earliest specific prespliceosome 
complex, although in the absence of other components, it can bind RNA in a nonspecific manner. SF2 
copurifies with an activity that promotes the annealing of complementary RNAs. Thus, SF2 may promote 
specific RNA-RNA interactions between snRNAs and pre-mRNA, between complementary snRNA regions, 
and/or involving intramolecular p e-mRNA helices. Other purified proteins with RNA annealing activity 
cannot substitute for SF2 in the splicing reaction. 
[Key Words: RNA splicing; splicing factors; SF2; in vitro complementation; spliceosome assembly; RNA 
annealing] 
Received March 23, 1990; revised version accepted April 27, 1990. 
Splicing of individual introns in eukaryotic pre-mRNAs 
takes place by a sequential two-step cleavage-ligation 
reaction, which has been reproduced m vitro {for re- 
views, see Green 1986; Padgett et al. 1986; Krainer and 
Maniatis 19881. In mammalian cell-free systems pre- 
mRNA splicing has been shown to require multiple nu- 
cleoprotein and protein factors {Kr/imer et al. 1984, 
1987; Black et al. 1985; Krainer and Maniatis 1985; 
Kr~imer and Keller 1985; Berget and Robberson 1986; 
Black and Steitz 1986; Perkins et al. 1986; Krainer 1988; 
Winkelmann et al. 1989). These splicing factors include 
the major nucleoplasmic small nuclear ribonucleopro- 
tein particles known as U snRNPs {Kr/imer et al. 1984; 
Krainer and Maniatis 1985; Black et al. 1985; Berget and 
Robberson 1986; Black and Steitz 1986; Krainer 1988; 
Winkelmann et al. 1989), which are composed of one or 
two U snRNAs and several common and unique poly- 
peptides {for reviews, see Lfihrmann 1988; Reddy and 
Busch 1988). The snRNPs have been purified extensively 
in their active forms {Krainer 1988; Winkelmann et al. 
1989}. Additional protein factors are also required for 
splicing (Krainer and Maniatis 1985; Kr/imer and Keller 
1985; Perkins et al. 1986; Kr/imer et al. 1987), but until 
now, none of these factors has been purified to homoge- 
neity in an active form; thus, their identities and modes 
ICorresponding author. 
of action are unknown. In addition, several HeLa cell 
polypeptides have been described and, in some cases, pu- 
rified, that interact with RNA specifically and/or are 
present in spliceosomes and are thus potential splicing 
factors (Choi et al. 1986; Gerke and Steitz 1986; Siera- 
kowska et al. 1986; Tazi et al. 1986; Kumar et al. 1987; 
Swanson and Dreyfuss 1988; Garcia-Blanco et al. 1989; 
Zamore and Green 1989; Fu and Maniatis 1990}. 
The snRNA components of U1 and U2 snRNPs base- 
pair to complementary sequences within conserved 
splicing signals on pre-mRNA, and these interactions 
have been shown to play a fundamental role in splice 
site recognition (Zhuang and Weiner 1986, 1989; Parker 
et al. 1987; Seraphin et al. 1988; Siliciano and Guthrie 
1988; Wu and Manley 1989). In addition, these and other 
snRNAs could potentially act as ribozymes, although it 
is not known at present whether RNA catalysis is in- 
volved in nuclear pre-mRNA splicing. Several of the 
protein factors mentioned above bind selectively to po- 
lypyrimidine-rich RNA and thus appear to be specific for 
pre-mRNA 3' splice sites (Choi et al. 1986; Gerke and 
Steitz 1986; Tazi et al. 1986; Kumar et al. 1987; 
Swanson and Dreyfuss 1988; Garcia-Blanco et al. 1989; 
Zamore and Green 19891. In theory, one or more of these 
factors can be involved in 3' splice site recognition, as 
well as in interactions with the usually adjacent branch 
site. It remains to be determined which of these RNA 
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and protein splicing factors contribute nzymatic activi- 
ties that are important for splicing and which factors 
contain the active sites for the catalysis of the RNA 
cleavage-ligation reactions. These fundamental ques- 
tions must be elucidated to provide a detailed under- 
standing of the mechanism of pre-mRNA splicing and to 
deduce the origin of pre-mRNA introns and their pos- 
sible evolutionary relations to self-splicing introns. 
To identify the factors that are absolutely required for 
pre-mRNA splicing in vitro, we and others have em- 
ployed complementation assays in which one or both 
cleavage-ligation reactions are restored upon addition 
of a purified or partially purified fraction (Krainer and 
Maniatis 1985; Kr~imer and Keller 1985; Perkins et al. 
1986; Kr~imer et al. 1987; Krainer 1988; Winkelmann et 
al. 1989). Although this type of functional assay is te- 
dious, we note that purification of factors on the basis of 
RNA binding or complex formation does not demon- 
strate a priori that such factors are essential for splicing. 
This is so even in cases in which RNA-binding proteins 
are involved in the formation of RNP complexes that 
behave as intermediates in the splicing pathway. A 
subset of such proteins could be involved in stabilizing 
the complexes o that they are detectable, but they do 
not necessarily play a direct role in splicing. In this 
study, we report the isolation and properties of an active 
protein splicing factor from HeLa cells. This factor, SF2, 
is shown to be an essential splicing factor required for 
cleavage at the 5' splice site and for lariat formation. 
Results and discussion 
Purification of SF2 
Previous work demonstrated that the cytoplasmic $100 
fraction obtained during the preparation of nuclear ex- 
tracts (Dignam et al. 1983) contains active snRNPs and 
other splicing factors but is deficient in at least one pro- 
tein activity, termed SF2, which is necessary for the first 
cleavage-ligation of pre-mRNA splicing (Krainer and 
Maniatis 1985). The reason for the selective retention of 
SF2 in the nuclear fraction in a hypotonic buffer is not 
known. It may be that the polypeptide(s) responsible for 
SF2 activity are tightly bound to the nuclear membrane 
Splicing factor SF2 
or to a subnuclear structure. Alternatively, SF2 could be 
part of large RNP complexes that cannot traverse the 
nuclear pores in an intact form. In fact, SF2 activity and 
other activities necessary for splicing cosediment with 
endogenous RNP particles and can be released by prein- 
cubation with ATP IConway et al. 1989). To facilitate 
the purification of SF2 we developed a new extraction 
procedure, which maximizes the recovery of SF2, as 
judged by titration of the extracts against a constant 
amount of complementing $100 fraction (see Materials 
and methods). From this extract, SF2 has been purified 
by ammonium sulfate precipitation, Sephacryl S200-HR 
gel filtration chromatography, Mono Q anion exchange 
chromatography, and Phenyl-Superose hydrophobic in- 
teraction chromatography (Table 1; Figs. 1 and 2; Mate- 
rials and methods). 
The activities and polypeptide composition of the 
various chromatographic fractions are shown in Figures 
1 and 2. The elution profile for the Phenyl-Superose 
column is shown in Figure 1. In the first active fraction, 
(Fig. 1A, fraction 9}, only a doublet of 33 kD is detectable 
by Coomassie Blue (Fig. 1B) or silver staining (not 
shown). Complementing activity peaked in fraction 10 
(Fig. 1A), which also corresponds to the 33-kD doublet 
peak (Fig. 1B). This fraction also contains several addi- 
tional high-molecular-weight polypeptides. Comple- 
menting activity is also detectable in fractions 11-13 
(Fig. 1A), although it did not correlate well with the 
abundance of the 33-kD doublet (Fig. 1B). A second peak 
of activity is centered in fraction 22 {Fig. 1A), which 
contains, among other minor bands, a polypeptide that 
comigrates precisely with the top band of the 33-kD 
doublet (Fig. 1B; data not shown). On the basis of these 
data, particularly the presence of complementing ac- 
tivity in fraction 9, we conclude that one or both of the 
33-kD polypeptides possesses SF2 activity. At this stage 
we cannot rule out the existence of very minor polypep- 
tides that are responsible for activity, although none 
were detected by silver staining. The reason for the dis- 
tribution of SF2 activity into two well-separated peaks is 
not known. 
The gel assay for splicing is not easily amenable to 
quantitation; thus, we cannot calculate precisely the 
overall purification of SF2. However, when SF2 is added 
in limiting amounts in the complementation assay, the 
Table 1. Purification of SF2 
Volume Protein Cumulative Cumulative 
Fraction {mlJ (mg) a yield (%)b purification 
I Crude extract 44 715 100 1 
II Ammonium sulfate 4 80 40 4 
III Sephacryl S200-HR 10 15 30 14 
IV Mono Q 2 10 25 18 
V Phenyl-Superose #9 1 0.03 5 1200 
aprotein concentrations were determined by the method of Bradford, in the linear range of dye binding, using BSA as a standard 
{Bradford 1976J. 
bThe approximate yi ld of SF2 activity was determined by the comparison of the extent of splicing in complementation assays with 
serial twofold dilutions of each fraction. 
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Figure 1. Purification of SF2. The Roman numerals denote pooled, active fractions from: crude extract {I); ammonium sulfate step 
(II); Sephacryl $200 HR step {III); Mono Q step (IV). The numbers 9-31 correspond to the Phenyl-Superose fractions; A and B are 
pooled flowthrough fractions 1-4 and 5-8, respectively. (A) SF2 complementation assay. Splicing reactions were carried out with 7.5 
~1 of the S100 extract supplemented with either 7.5 Ixl of the indicated Phenyl-Superose fractions or with 3.75 ~1 of I, 3 ~1 of II, 7.5 ~1 
of III, or 1 ~1 of IV. The positions of the [3-globin pre-mRNA, intermediates, and products of splicing are indicated at left. (B) Polypep- 
tide composition. The proteins in the indicated fractions were analyzed by SDS-PAGE and Coomassie Blue staining. (M) Molecular 
weight markers; (III} 10 Ixl of fraction III; (W) 2.5 txl of fraction W; the remaining lanes contain 10 ~1 of the indicated fractions. 
amount of spliced mRNA generated is roughly propor- 
tional to the concentration f SF2. Titration of the SF2- 
containing fractions against a constant amount of S100 
can give an indication of the concentration of SF2 in 
each fraction. However, because the complementation 
assay involves addition of a crude S100 extract, these es- 
timates are affected in an unpredictable manner by non- 
specific protein-RNA and protein-protein teractions. 
Furthermore, the yield of spliced mRNA is affected by 
the presence of ribonucleases in the S100 extract and in 
the partially purified nuclear fractions. Often, when 
splicing is inefficient, the pre-mRNA is susceptible to 
degradation, suggesting that spliceosome formation pro- 
tects the pre-mRNA from endogenous nucleases. With 
these caveats in mind, it is nevertheless useful to esti- 
mate the yield of SF2 during the various purification 
steps (Table 1; Fig. 2). There is roughly a 24,000-fold re- 
duction in protein, when comparing the crude extract o 
the Phenyl-Superose fraction 9 (Table 1). Serial 2-fold 
dilutions of the complementing fractions indicate that 
-5% of the initial SF2 is recovered in fraction 9, for an 
overall purification of 1200-fold. The overall yield of SF2 
activity is -20%, when the other active Phenyl-Su- 
perose fractions are considered (Fig. 1; data not shown). 
A small amount of endogenous heterogeneous nuclear 
RNA (hnRNA) copurified with the SF2 polypeptides (see 
below), but SF2 activity does not appear to require an 
essential RNA component, as judged by its resistance to 
micrococcal nuclease treatment (Krainer and Maniatis 
1985). Following inactivation of the nuclease by calcium 
chelation, purified SF2, like crude SF2, was fully active 
in the complementation assay (data not shown). In con- 
trast, SF2 activity was susceptible to papain digestion. 
Following inactivation of the protease with a specific in- 
hibitor, digested SF2 failed to complement the S100, 
whereas preinactivated papain had no effect (data not 
shown). 
The similarity in the apparent molecular weights of 
the SF2 polypeptides and those reported for the hnRNP 
A1 (for review, see Dreyfuss et al. 1988) and for the U1 
snRNP A polypeptides (for review, see Liihrmarm 1988) 
prompted us to compare them by SDS-PAGE analysis 
(Fig. 2, lanes 6-9). Both SF2 polypeptides are slightly 
smaller than hnRNP A1 and slightly larger than A, both 
derived from HeLa cells. The true molecular masses 
of A1 and A are 34,214 and 31,243 daltons, respectively, 
as derived from their cDNA sequences (Sillekens et al. 
1987; Cobianchi et al. 1988). In addition, the SF2 poly- 
peptides did not react in a Western blot analysis, using 
an anti-hnRNP antiserum that recognizes all the core 
hnRNP proteins (data not shown). 
SF2 is a general splicing factor 
The complementation assay employed for the purifica- 
tion of SF2 relied exclusively on a pre-mRNA substrate 
containing the first two exons and first intron of human 
13-globin. It was important to determine whether the re- 
quirement for SF2 is substrate dependent, and to this 
end, several different pre-mRNAs were spliced in vitro. 
An example of this is shown in Figure 3. A human im- 
munodeficiency virus- 1 (HIV- 1) pre-mRNA, containing 
the coding exons of the tat gene and a truncated intron, 
was completely dependent on SF2 for splicing (lanes 5 
and 6). In the S100 extract alone, no specific cleavage 
related to splicing was observed (lane 6). Unlike the [3- 
globin pre-mRNA, which spliced equally well in the re- 
constituted system and in the nuclear extract (lanes 1 
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This pre-mRNA was stable in the reconstituted system, 
but it was spliced less efficiently than with nuclear ex- 
tract. 
Figure 2. SDS-PAGE analysis ofSF2 fractions and HeLa RNPs. 
(Lane 1) Molecular weight markers (M); (lane 2) crude extract, 
0.1 x (1 x = 2.4 x 10 z cell equivalents); (lane 3) ammonium 
sulfate active fraction, 1 x; {lane 4) Sephacryl $200 HR 
pooled active fraction, 1 x ; {lane 5) Mono Q pooled active frac- 
tions, 1 x; {lanes 6 and 9) Phenyl-Superose fraction 9, 10 x; 
(lane 7) purified HeLa cell hnRNP particles (0.03 A26o units); 
(lane 8) purified HeLa cell U snRNP particles (1.25 x 108 cell 
equivalents), hnRNP A1 and U1 snRNP A polypeptides are in- 
dicated by arrowheads. 
SF2 is required for spliceosome formation 
The complementation assay employed for the purifica- 
tion of SF2 indicates that this activity is required for 
cleavage of pre-mRNA at the 5' splice site and lariat for- 
mation. This reaction is normally preceded by the as- 
sembly of specific prespliceosome and spliceosome 
complexes, in which pre-mRNA interacts in a stable 
manner with multiple components of the splicing appa- 
ratus, such as the U snRNPs (for reviews, see Green 
1986; Padgett et al. 1986; Krainer and Maniatis 1988}. To 
determine the requirement for SF2 in this assembly 
pathway, RNP complexes were analyzed by a gel-retar- 
dation assay (Fig. 4). Under these electrophoretic condi- 
tions, three specific complexes are normally detected 
(Fig. 4, lane 2; Zillman et al. 19881. When pre-mRNA 
was incubated with the $100 extract under splicing con- 
ditions, no specific complexes were detected (lane 31. In- 
cubation of pre-mRNA with purified SF2 also failed to 
generate specific complexes of discrete mobility [lane 4). 
The smear detected under these conditions is consistent 
with nonspecific RNA binding by SF2 (see below). When 
pre-mRNA was incubated with purified SF2 and S100, 
three discrete complexes were detected, which have the 
and 2), the HIV pre-mRNA was spliced much more effi- 
ciently in the reconstituted system (lanes 4 and 5). When 
nuclear extract was supplemented with additional puri- 
fied SF2, there was no effect on the splicing efficiency of 
the ~-globin pre-mRNA, whereas the HIV pre-mRNA 
was spliced as efficiently as with S100 and SF2 {data not 
shown}. Therefore, higher amounts of SF2 are required 
for efficient splicing of the HIV pre-mRNA than for the 
B-globin pre-mRNA. 
The inefficient splicing of the HIV pre-mRNA in nu- 
clear extracts may reflect a general property of retroviral 
transcripts which, unlike most cellular pre-mRNAs, are 
spliced inefficiently to provide unspliced transcripts that 
are required for viral replication, packaging into virions, 
and expression f several proteins (for review, see Weiss 
et al. 19821. Retroviral cis-actmg sequences appear to be 
responsible for inefficient splicing (Arrigo and Beemon 
1988; Stoltzfus and Fogarty 1989; Katz and Skalka 1990). 
Our data suggest hat in some cases, this type of nega- 
tive cis-acting element may relate to the function of SF2. 
In addition to these substrates, SF2 was found to be 
required for splicing both introns of rabbit [3-globin pre- 
mRNA [data not shownl and several introns from a rat 
~-tropomyosin pre-mRNA (D. Helfman and A.R. 
Krainer, unpubl.). We were unable to demonstrate a re- 
quirement for SF2 to splice the adenovirus major late 
first intron, due to the instability of this pre-mRNA in 
the S100 extract in the absence of SF2 {data not shown). 
Figure 3. SF2-dependent splicing of tw  different pre-mRNAs. 
Human [3-globin pre-mRNA Ilanes 1-3), or an HIV-1 pre- 
mRNA derived from the tat region (lanes 4-61 were spliced 
with the indicated extracts and purified SF2, and theproducts 
were analyzed by urea-PAGE. The structures of the precursors, 
intermediates, and products of splicing are displayed on ach 
side of the autoradiograph. The band indicated by the arrow- 
head above HIV mRNA is not a lariat intermediate but a trun- 
cated pre-mRNA arising from artifactual cleavage. 
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complementing S100 extract were added. The kinetics 
and extent of splicing of each substrate were the same 
[data not shown). Thus, SF2, itself, does not form a com- 
mitted complex with pre-mRNA that persists through a 
rate-limiting step in splicing. In a reciprocal experiment, 
preincubations were done with the S100, and SF2 was 
added later with the second pre-mRNA. Again, no differ- 
ences were detected in the splicing of the first and 
second substrate {data not shown}, suggesting that no 
stable specific complexes are formed in the absence of 
SF2, in agreement with the native gel analysis. Further 
experiments are necessary to determine whether SF2 re- 
mains stably associated with the spliceosome alter pro- 
moting the assembly of the initial specific complex and 
whether it is recycled to participate in a new round of 
splicing. The minimum amount of purified SF2 that is 
necessary to complement the S100 fraction represents a 
slight molar excess over the pre-mRNA concentration, 
suggesting that SF2 may act stoichiometrically, rather 
than catalytically. However, we do not know what pro- 
portion of the purified molecules is active, and further- 
more, a fraction of these molecules may become trapped 
in nonproductive complexes upon addition to the crude 
S 100 fraction. 
Figure 4. Spliceosome assembly. Human 13-globin pre-mRNA 
was incubated for 45 min under splicing conditions, with the 
indicated fractions. The resulting complexes were analyzed by 
native gel electrophoresis, as described (Zillman et al. 1988). 
{Lane l J Pre-mRNA alone; (lane 2) nuclear extract; {lane 3J S100 
extract; {lane 4) purified SF2; {lane 5), S100 extract plus purified 
SF2. The electrophoretic positions f free RNA and of com- 
plexes I, A, A', and B {Zillman et al. 1988) are indicated. 
same mobility as the A, A', and B complexes obtained 
with the nuclear extract (lane 5). We conclude that SF2 
is required for the assembly or the stabilization of the 
earliest specific complex in the spliceosome assembly 
pathway, which is thought o be the A complex (Zillman 
et al. 1988). The intensity of the bands was much lower 
with the reconstituted system than with the crude nu- 
clear extract (cf. lanes 2 and 5), although the extent of 
splicing was very similar in both cases {Fig. 3, lanes 1 
and 2). This may simply reflect differences in the 
steady-state levels of the complexes formed in each reac- 
tion. Alternatively, the stability of these complexes may 
be different because of the influence of other specific and 
nonspecific components in each reaction. It is likely 
that the native gel assay conditions result in partial dis- 
assembly of the complexes. 
Preincubation experiments with globin pre-mRNAs of 
different sizes were carried out to determine whether 
SF2 forms a stable, committed complex with pre- 
mRNA. Each pre-mRNA was preincubated with lim- 
iting amounts of SF2 in the presence or absence of ATP 
and magnesium, and then the second pre-mRNA and the 
RNA-binding properties of SF2 
The effects of SF2 on splicing and splicing complex as- 
sembly may involve direct interactions between this 
factor and the pre-mRNA substrate, or SF2 may act 
without associating with the spliceosome, .g., by modi- 
fying other factors. To determine whether SF2 binds 
RNA, several types of analyses were carried out. UV 
cross-linking demonstrated direct binding of purified 
SF2 to pre-mRNA and to mRNA (Fig. 5}. When the 
cross-linked material is digested extensively with ribo- 
nuclease A, the protein-oligoribonucleotide adducts 
usually comigrate with, or migrate slightly behind, the 
untreated polypeptides on SDS-PAGE {Greenberg 1980; 
Economides and Pederson 1983; Choi and Dreyfuss 
1984; Garcia-Blanco et al. 1989). In the case of SF2, the 
mobility of the labeled adducts appears lightly slower 
than that of the untreated 33-kD doublet. At least one 
and, possibly, both polypeptides were cross-linked to 
pre-mRNA and to mRNA (Fig. 5, lanes 2 and 4). The 
poor resolution of the bands makes it difficult to deter- 
mine to what extent each of the polypeptides i cross- 
linked. It is possible that only one polypeptide binds 
RNA, in which case the heterogeneity of the labeled ad- 
ducts may be due to binding to different regions of the 
labeled RNA, which would give rise to heterogeneous 
RNase A digestion products. Thus, for instance, rela- 
tively nonspecific RNA binding and/or partial protec- 
tion from RNase A could account for the observed pat- 
tern even if only the smaller of the two polypeptides 
binds RNA. A lighter band was also detected with an 
electrophoretic mobility expected for a protein dimer, 
and on longer exposures, labeled material with the mo- 
bility of trimers, tetramers, etc., was also seen. These 
forms could arise ither by a low level of protein-pro- 
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Figure 5. UV cross-linking. 32P-labeled human ~-globin pre- 
mRNA or mRNA BamHI runoff transcripts were incubated 
with nuclease-free bovine serum albumin or with purified SF2 
for 15 min and irradiated at 254 nm. After digestion with 
RNase A, the products were analyzed by SDS-PAGE and autora- 
diography. The electrophoretic mobilities of the untreated 
33-kD polypeptides and of unlabeled molecular weight markers 
are indicated. 
tein cross-linking or by protection from RNase A of 
small RNA fragments bound by two or more adjacent 
SF2 molecules. 
These experiments gave the appearance of more effi- 
cient cross-linking to mRNA than to pre-mRNA (Fig. 5, 
cf. lanes 2 and 4). Both RNAs were labeled to the same 
specific activity with all four ribonucleoside triphos- 
phates. However, the extent ofRNase digestion could be 
different for each RNA, depending on, among other 
things, the distribution of pyrimidines in the vicinity of 
each cross-link. As a result, the molar amount of a2p 
label in each adduct may differ, creating the appearance 
of different crossqinking efficiencies. Even if the cross- 
linking efficiencies do differ, this is not necessarily a re- 
flection of different binding efficiencies, as some protein 
molecules may bind specific RNA sequences but they 
may fail to be cross-linked ue to the specific bases and 
amino acid side chains present at or near the contact 
points. It is possible, although not directly addressed in 
these cross-linking experiments, that SF2 binding re- 
flects the higher order structure of these RNAs or, 
perhaps, preferential binding to the spliced exon borders. 
The solution structure of naked human ~-globin pre- 
mRNA truncated at the BamHI site in exon 2 has been 
determined (Teare and Wollenzien 1989), and it includes 
helices between intron 1 and exon 2. Therefore, the so- 
lution structures of the exons in pre-mRNA and mRNA 
are substantially different. 
No RNA binding was detected by Northwestern blot- 
ting, which could have been due to poor renaturation of
Splicing factor SF2 
each polypeptide after SDS-PAGE (data not shown). Al- 
ternatively, both polypeptides might be necessary for 
RNA binding. We have not been able to separate the two 
polypeptides by nondenaturing techniques; thus, we 
cannot presently determine whether only one or both 
are responsible for the observed activities. We note, 
however, that preliminary amino acid analysis of the in- 
dividual electrophoretically separated polypeptides sug- 
gests that they are related (data not shown). RNA foot- 
printing experiments were carried out by partial modifi- 
cation of globin pre-mRNA with dimethylsulfate, 
followed by primer extension, and by partial digestion of 
end-labeled pre-mRNA with ribonucleases. No specific 
footprint was observed in the presence of SF2, suggesting 
that at least in the absence of other components, SF2 
does not bind pre-mRNA in a sequence-specific manner 
(data not shown). However, because we do not know 
what fraction of the SF2 molecules is active in these ex- 
periments and because detection of a footprint requires 
binding to most or all of the RNA molecules, the possi- 
bility that SF2 binds RNA in a sequence-specific manner 
cannot be ruled out at present. 
SF2 copurifies with an RNA annealing activity 
We tested purified SF2 for possible RNA helicase and/or 
annealing activities (Fig. 6). Complementary ~2P-labeled 
RNAs were incubated with purified SF2 in splicing 
buffer, in the presence or absence of ATP. After incuba- 
tion, digestion with ribonuclease T1 was carried out, 
and nuclease-resistant double-stranded RNAs were de- 
tected by urea-PAGE. In the absence of protein, com- 
plementary RNAs do not anneal in these buffer condi- 
tions at 30~ (Fig. 6, lanes 3 and 5), due to the higher 
order structures of the individual strands and to the slow 
rate of annealing at temperatures substantially below 
the melting temperature. Efficient annealing requires an 
initial incubation at high temperature to eliminate these 
intramolecular helices, followed by incubation at -25 ~ 
below the melting temperature. The theoretical melting 
temperature in these experiments is 86~ or higher 
when magnesium is taken into account (for review, see 
Wahl et al. 1987). However, in the presence of SF2, rapid 
annealing can take place at 30~ with or without ATP 
(Fig. 6, lanes 4 and 6) and only in the presence of magne- 
sium (data not shown). When the complementary 
strands were preannealed, SF2 did not melt them, even 
when ATP was present (lanes 8 and 10). In summary, 
SF2 lowers the activation energy for intermolecular 
RNA duplex formation and thus behaves as a magne- 
sium-dependent and ATP-independent RNA annealing 
activity. Under the conditions tested, SF2 lacks RNA 
helicase activity, as well as RNA-dependent ATPase ac- 
tivity (Fig. 6; data not shown). 
To test further whether the RNA annealing activity is 
intrinsic to SF2 or whether it is a contaminating ac- 
tivity, we repeated the purification and assayed each 
fraction for both complementation f the S100 and for 
RNA annealing. Although other RNA annealing activi- 
ties were present in the nuclear extract (Munroe 1988) 
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Figure 6. RNA annealing and helicase assays. Sense and anti- 
sense complementary B-globin RNAs were incubated as sepa- 
rate strands or as a preannealed duplex in the presence or ab- 
sence of purified SF2 and ATP, as described in the text and dia- 
gram. After digestion with ribonuclease T1, the products were 
analyzed by urea-PAGE and autoradiography. T e positions of
the untreated sense and antisense RNAs and of the Tl-resistant 
duplex are indicated on each side of the autoradiograph. 
and in several of the Phenyl-Superose fractions lacking 
SF2 (data not shown), one such activity copurified pre- 
cisely with SF2 (Fig. 7A, B). Both activities peaked in 
fractions 24-28 and were reduced in fraction 26. Both 
activities correlate well with the 33-kD polypeptides in
fractions 24 and 25 (Fig. 7C, D); however, it is difficult to 
detect hese bands in fractions 27 and 28. It is not pos- 
sible to assign activities to polypeptides in these frac- 
tions, but possible candidates are minor polypeptides of
55 (see below), 36, and 24 kD. Further experiments are 
necessary to determine whether these polypeptides are 
related to one another. A 32-kD polypeptide that peaks 
in fraction 23 is inactive (Fig. 7A-D) and may represent 
a degradation product of the 33-kD polypeptides. It is 
present in only some preparations (Fig. 7C, D, fractions 
23-25 and lane C; Fig. 1). 
Although the majority of the nuclear RNA in the 
crude extract was removed in the initial chromato- 
graphic steps, a small amount of UV2so-absorbing mate- 
rial copurified with SF2 and with the annealing activity. 
Therefore, the RNA content of the Phenyl-Superose 
fractions was analyzed by urea-PAGE (Fig. 7E). A smear 
corresponding tohnRNA is present in all the active frac- 
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tions, and some, but not all, active fractions also contain 
discrete RNA species of tRNA size or larger. Thus, SF2 
is not likely to have an essential RNA component, in 
agreement with its resistance to micrococcal nuclease 
{Krainer and Maniatis 1985; this study). 
The 34-kD hnRNP A1 protein has been shown to have 
helix-destabilizing properties on double-stranded RNA. 
Likewise, proteolytic fragments of hnRNP A1, termed 
HDPs, or helix-destabilizing proteins, can lower the 
melting temperature of both double-stranded RNA and 
DNA (Cobianchi et al. 1988, and references therein). 
Under suitable conditions, this lowering of the melting 
temperature by hnRNP A1 can promote RNA annealing 
(S. Munroe, pers. comm.1. We therefore tested purified 
A1 {kindly provided by S.Wilson) to see whether it could 
substitute for SF2 in the splicing complementation a d 
RNA annealing assays. Concentrations of A1 that were 
active in RNA annealing did not substitute for SF2 in 
the complementation assay {data not shown}. These ob- 
servations uggest hat if RNA annealing activity is in- 
tegral to SF2 and necessary for splicing, it is not suffi- 
cient, implying that specific protein-protein or pro- 
te in-RNA interactions are involved in mediating the 
role of SF2 in splicing. 
Further experiments are necessary to elucidate the 
precise substrate specificity, if any, of the SF2 RNA an- 
nealing activity. However, we can envisage three types 
of potential complementary RNA targets upon which 
the SF2 RNA annealing activity could act to mediate its 
effects on splicing. First, at least two snRNA-pre- 
mRNA helices are known to form during splicing and to 
contribute to splice site selection; these involve base- 
pairing interactions between the 5' terminus of U1 
snRNA and pre-mRNA 5' splice sites {Zhuang and 
Weiner 1986; Seraphin et al. 1988; Siliciano and Guthrie 
1988) and between an internal region of U2 snRNA and 
pre-mRNA branch site sequences {Parker et al. 1987; Wu 
and Manley 1989; Zhuang and Weiner 19891. Second, U4 
and U6 snRNAs coexist in a single snRNP particle held 
together by intermolecular base pairs {Bringmann et al. 
1984; Hashimoto and Steitz 19841, and there is some vi- 
dence that the U4 subunit may be released from the 
spliceosome during the course of splicing, possibly to be 
recycled {Cheng and Abelson 1987; Konarska and Sharp 
1987; Lossky et al. 1987; Lamond et al. 1988; Black and 
Pinto 1989; Blencowe et al. 1989). Third, pre-mRNA 
may be recognized as a proper splicing substrate only 
when it adopts a defined secondary and tertiary struc- 
ture. Some of the putative intramolecular RNA helices 
may preferentially expose the splice sites and branch 
site. 
Immunoprecipitation of SF2 
To facilitate the characterization f native SF2 and to 
determine whether the 33-kD polypeptides are normally 
associated with other known or unknown polypeptides, 
polyclonal antisera were obtained by immunization of 
rabbits with purified SF2. After repeated injections, SF2 
antisera were obtained and used for immunoprecipita- 
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Figure 7. Copurification of SF2 and RNA annealing activities. Selected fractions from the Phenyl-Superose column were tested for 
complementing activity in splicing with the Sl00 extract (A) and for RNA annealing (B). The polypeptide composition of the same 
column fractions is shown in C (Coomassie Blue staining) and D (silver staining). (E) RNAs present in these fractions. The following 
amounts of each fraction were used: 7.5 p.1 (A), 15 ~1 (B), and 30 p.1 (C-E). The elution conditions for this column were slightly 
different from those in Fig. 1. Numbers at top of A-E are the fraction numbers. (FT) Flowthrough fraction; (NE) nuclear extract; (C) 
different purified preparation of SF2; (M) molecular weight markers with the indicated sizes. The amount of NE used in E represents 
100 times fewer cell equivalents han the amount of each fraction. The positions of tRNAs and U1 and U2 snRNAs are indicated. 
tions of asS-labeled HeLa cell nuclear extracts (Fig. 8). 
The SF2 antiserum immunoprecipitated a doublet of 
proteins of -33 kD, as well as a polypeptide of 55 kD, 
which migrates more slowly than IgG heavy chain (lane 
2). A 55-kD polypeptide could not be detected in the SF2 
preparation employed for immunization. Its presence in 
the immunoprecipitates could be explained by contami- 
nation of the purified preparation with trace amounts of 
a highly antigenic protein. Alternatively, the 55-kD 
polypeptide may be a subunit of native SF2 that is asso- 
ciated with one or both 33-kD polypeptides in vivo. If 
this putative subunit is necessary for activity, it would 
have to associate with the purified 33-kD polypeptides 
upon incubation with the crude S100 fraction. An alter- 
native explanation for the presence of the 55-kD band in 
the immunoprecipitates is that one or both 33-kD poly- 
peptides may be specific proteolytic products of a puta- 
tive 55-kD or larger SF2 precursor. Finally, the 55- and 
33-kD proteins may share one or more epitopes. These 
possibilities can be explored by Western blotting anal- 
ysis. Unfortunately, none of the SF2 antisera we have 
obtained so far are reactive in this type of analysis. We 
note that while optimizing the purification of SF2 we 
observed a 55-kD polypeptide that copurified precisely 
with highly purified 33-kD polypeptides (data not 
shown). In the procedure that was optimized for SF2 ac- 
tivity (Figs. 1 and 7), a 55-kD polypeptide was no longer 
detected in the fractions with maximal activity and the 
largest amount of the 33-kD polypeptides. However, a 
small amount of a 55-kD polypeptide can be seen in ad- 
jacent fractions and may account for their activity in the 
complementation a d annealing assays. Further work is 
necessary to determine the r lation between the 33- and 
55-kD polypeptides. 
Relation of SF2 to other factors and activities 
SF2 can be compared to other factors and activities on 
the basis of reported biochemical and physical proper- 
ties. One distinguishing feature of SF2 is its apparent re- 
tention in the nuclear fraction until the salt concentra- 
tion is raised in the extraction buffer (Krainer and Man- 
iatis 1985). In our hands, the cytoplasmic S100 extract 
lacks a single component required for splicing, as as- 
sayed by complementation, but we believe that the 
ability to detect other components identified by dif- 
ferent assays is likely to be variable. The relative con- 
centration of various splicing factors is very different in 
nuclear and S100 extracts, but only SF2 is limiting for 
splicing in the latter extract. We have found, for ex- 
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Figure 8. Immunoprecipitation of SF2. A nuclear extract pre- 
pared from HeLa cells labeled with [sSS]methionine and cys- 
teine was immunoprecipitated with rabbit preimmune serum 
(lane 1) or with antiserum from the same rabbit immunized 
with purified SF2 (lane 2). The immunoprecipitates were recov- 
ered and analyzed by SDS-PAGE and fluorography. The sizes of 
the immunoprecipitated polypeptides (in kilodaltons) relative 
to unlabeled markers, as well as the position of immunoglob- 
ulin heavy chain, are indicated. 
ample, that hnRNP C protein is also greatly reduced in 
$100 extracts (G.C. Conway and A.R. Krainer, unpubl.), 
yet we know that SF2 and C proteins are distinct. Thus, 
either C protein is not necessary for splicing or the small 
amount in the $100 extract is sufficient for activity 
(Choi et al. 1986; Sierakowska et al. 1986). We also note 
that there may be subtle differences in the composition 
of $100 extracts prepared in different laboratories. 
Therefore, the putative identity of other factors and SF2 
should not be inferred solely on the basis of similar sub- 
cellular fractionation. 
Splicing factors assayed by cornplementation The SF2 
polypeptides do not comigrate with any known snRNP 
polypeptide, and they do not copurify with snRNAs 
(Figs. 2 and 7E). This is in agreement with the observa- 
tion that SF2 activity can be chromatographically sepa- 
rated from active snRNPs (Krainer 1988). Immunopreci- 
pitation of the SF2 polypeptides under mild conditions 
does not bring down snRNP polypeptides, and con- 
versely, immunoaffinity-purified snRNPs do not contain 
SF2 polypeptides (Figs. 2 and 8). Thus, the majority of 
SF2 and snRNPs do not appear to coexist in stable par- 
ticles in the nuclear extract, and they may or may not 
contact each other upon spliceosome assembly. 
In regard to non-snRNP factors that have been shown 
to be required for splicing by complementation, conclu- 
sive comparisons to SF2 are not always possible at this 
stage, because none of these factors have been identified 
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at the polypeptide level. On the basis of chromato- 
graphic properties, webelieve that SF2 is present in frac- 
tion II described by Perkins et al. (1986), together with 
snRNPs and other protein factors. The factor described 
in the present study is different from a partially purified 
component, coincidentally designated SF2 (Kfiimer and 
Keller 1985), which, unlike our factor, is enriched in the 
cytoplasmic fraction and is sensitive to the sulfhydryl 
reagent N-ethyl maleimide (NEM). Kr/imer and col- 
leagues also described two partially purified components 
necessary for splicing, termed SF1 and SF3, which, to- 
gether with a fraction containing U2 snRNP, are mini- 
mally required to form a stable complex with pre- 
mRNA (Kr~imer et al. 1987; Kr~imer 1988). The com- 
bined activity of these two components i thought to 
correspond to a binding activity designated U2AF 
(Kriimer 1988; Ruskin et al. 1988; see below). On the 
basis of the reported chromatographic and subcellular 
fractionation properties, it is possible that Kr~imer's SF1 
factor corresponds to SF4B described elsewhere (Krainer 
and Maniatis 1985); whereas her SF3 factor is potentially 
analogous to the SF2 activity described in the present 
study (Krainer and Maniatis 1985; Kr~imer et al. 1987; 
Kroner 1988; this study). Other splicing activities desig- 
nated SF3 and SF4A were shown previously to be dis- 
tinct from SF2 (Krainer and Maniatis 1985). SCF, an ac- 
tivity necessary to complement presumptive in vivo as- 
sembled spliceosomes (Zeitlin et al. 1989) is thought o 
be related to SF1 (Kr~imer et al. 1987) and distinct from 
SF2 (Krainer and Maniatis 1985; Zeitlin et al. 1989; this 
study). 
hnRNP and intron-binding proteins Several RNA- 
binding proteins may play a role in splicing, as inferred 
from their sequence-specific binding properties. Among 
these are the core hnRNP proteins, as well as several 
additional constituents of hnRNP particles (for review, 
see Dreyfuss et al. 1988; Kumar et al. 1987; Swanson and 
Dreyfuss 1988). Pifiol-Roma et al. (1988) isolated mul- 
tiple HeLa RNA-binding proteins present i  hnRNP par- 
ticles and characterized them by two-dimensional gel 
analysis. Because SF2 appears to be present in RNP par- 
ticles in nuclear extracts (Conway et al. 1989; this 
study), it may be one of the known hnRNP proteins. 
However, the 33-kD polypeptides are smaller than all of 
the two dozen or so HeLa hnRNP polypeptides described 
by Pifiol-Roma et al. (1988). Although they may repre- 
sent proteolytic products of one of the larger hnRNP 
proteins, another possibility is that the SF2 polypeptides 
were not detected previously as hnRNA-binding pro- 
teins due to their low abundance or poor labeling with 
[3sS]methionine. The SF2 polypeptides migrate slightly 
ahead of the hnRNP core protein A1 (Fig. 2), which is the 
smallest of the known hnRNP proteins. However, degra- 
dation products of A1, ranging in size from 20 to 33 kD, 
have also been described (Gobianchi et al. 1988, and ref- 
erences therein). We used a polyclonal A1 antiserum for 
Western blot analysis and observed no cross-reactivity 
with the 33-kD proteins, even though this antiserum 
reacted strongly with all the core hnRNP polypeptides. 
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A family of RNA-binding proteins that bind preferen- 
tially to 3' splice sites and may exist in association with 
U5 snRNP has been described. These proteins have not 
been purified extensively, but they have been character- 
ized by Northwestern blotting analysis and have re- 
ported molecular masses of 70 and 110 kD (Gerke and 
Steitz 1986; Tazi et al. 1986). None of their physical, bio- 
chemical, or chromatographic properties uggest a simi- 
larity to the SF2 polypeptides. The same can be said of a 
recently isolated RNA-binding protein of 62 kD, or 
pPTB, which cross-links at 3' splice sites and is present 
in spliceosomes (Garcia-Blanco et al. 1989). 
U2AF An activity termed U2AF was originally identi- 
fied in crude nuclear extracts by a ribonuclease protec- 
tion assay and was shown to protect the branch site re- 
gion in combination with extracts containing U2 snRNP 
and to participate in splicing complex assembly (Ruskin 
et al. 1988). U2AF was reported to be absent or reduced 
in S100 extracts, and is sensitive to NEM (Ruskin et al. 
1988). In contrast, SF2 activity is unaffected by treat- 
ment with NEM (data not shown). However, we note 
that the sensitivity of U2AF to NEM could have been 
due to inactivation of endogenous creatine kinase, 
which is necessary for ATP regeneration i splicing ex- 
tracts (Krainer et al. 1984). This enzyme contains an es- 
sential reactive cysteine (Kumudavalli et al. 1970), and 
ATP is required for the binding of U2 snRNP to the 
branch site (Black et al. 1985). It is not known at present 
whether U2AF is an essential splicing factor, although 
Kr~imer has obtained two partially purified protein frac- 
tions necessary for splicing which, when combined, also 
have U2AF-like activity (Kr/imer 1988). U2AF was re- 
ported to bind in a sequence-specific manner to the 3' 
splice site (Ruskin et al. 1988). In contrast, we do not 
detect sequence specificity in the binding of SF2 to RNA 
(Fig. 5), but different RNA-binding assays were em- 
ployed in each case. Two polypeptides of 65 and 35 kD 
were recently purified on the basis of a gel mobility shift 
assay and a UV cross-linking assay (Zamore and Green 
1989), and may correspond to the U2AF activity de- 
scribed originally (Ruskin et al. 1988). The 65-kD com- 
ponent may be analogous to pPTB (Garcia-Blanco et al. 
1989). It is possible, although unknown at present, that 
the 35-kD component is the same as, or related to, the 
33-kD SF2 polypeptides described in the present study. 
However, the 35-kD polypeptide does not cross-link to 
RNA (Zamore and Green 1989), in contrast to the 33-kD 
polypeptides (Fig. 5). In addition, we have found that SF2 
mediates ome of its effects at the 5' splice site (Krainer 
et al. 1990). In this respect, SF2 may be related to activi- 
ties present in the nuclear extract, which enhance the 
binding of U1 snRNP to 5' splice sites (Mayeda et al. 
1986; Zapp and Berget 1989). 
SC-35 Recently, Fu and Maniatis obtained a mono- 
clonal antibody against a protein, termed SC-35, that is 
stably associated with spliceosome complexes (Fu and 
Maniatis 1990). Immunodepletion f SC-35 from nuclear 
extracts results in loss of splicing activity and reduces 
Splicing factor SF2 
the efficiency of complex formation, suggesting that this 
antigen or other nuclear proteins associated with it are 
necessary for splicing. Immunodepleted xtracts could 
be complemented by micrococcal nuclease-treated nu- 
clear extract but not by S100 extract, suggesting that 
SC-35 may be the same as SF2 or associated with it, for 
example, in an endogenous RNP complex (Conway et al. 
1989). On Western blots, the aSC-35 antibody reacts 
with a 35-kD doublet in nuclear but not cytoplasmic ex- 
tracts (Fu and Maniatis 1990). The similarity in size and 
other properties raises the possibility that this antigen 
and the 33-kD SF2 polypeptides may be the same or re- 
lated. Experiments are in progress to address this possi- 
bility. 
Conclusions 
The complementation strategy employed here allowed 
us to isolate a factor that is essential for 5' splice site 
cleavage and lariat formation in vitro. It is always diffi- 
cult to rule out completely the possibility of in vitro ar- 
tifacts, and we do not know at present whether SF2 is 
required for splicing in vivo. However, we have recently 
found that SF2 mediates highly specific effects on splice 
site selection (Krainer et al. 1990). SF2 was found to be 
absolutely required for the splicing of several different 
introns. The S 100 extract plus purified SF2 reconstituted 
system provides an alternative to nuclear extracts for in 
vitro splicing studies. We found that some pre-mRNAs 
spliced much more efficiently in this system than in nu- 
clear extract. For example, splicing of an HIV-derived 
pre-mRNA was almost undetectable in nuclear extract 
and quite efficient in the reconstituted system; this was 
directly attributable to differences in the concentration 
of SF2. The opposite extract preference was observed 
with an adenovirus pre-mRNA, suggesting that the two 
in vitro systems probably differ in the relative concen- 
trations of several splicing factors. 
The precise mode of action of SF2 is unknown. Our 
current data indicate that SF2 has nonspecific RNA 
binding properties and the ability to promote annealing 
of complementary RNA strands. It does not form a 
stable complex with pre-mRNA in the absence of other 
factors, but the earliest requirement for SF2 appears to 
be for the assembly or stabilization of the pre-spliceo- 
some complex. The associated RNA annealing activity 
suggests that SF2 may alter the higher order structure of 
the pre-mRNA substrate and/or the snRNAs. The 33-kD 
polypeptides represent minimal units of structure and 
complementing activity, and they retain RNA-binding 
and annealing functions. Whether these polypeptides 
must directly associate with other factors or subunits to 
promote splicing remains to be determined. 
Materials and methods 
Cell growth and sonicated nuclear extract preparation 
HeLa S3 cells were grown i  spinner flasks in Dulbecco's 
modified minimal essential medium (DMEM) supplemented 
with 5% calf serum. They were harvested ata density of 106/ml 
GENES & DEVELOPMENT 1167 
 Cold Spring Harbor Laboratory Press on December 10, 2013 - Published by genesdev.cshlp.orgDownloaded from 
Krainet et al. 
by centrifugation at2500 rpm (1819gm~) in a Sorvall H-6000A 
rotor for 10 min at 4~ The cell pellet was resuspended in 50 % 
(vol/vol) glycerol and 1 x DMEM {50 ml final volume per 3 
liters of original culture) and stored at - 70~ Freezing the cells 
indefinitely in this manner did not adversely affect he splicing 
activity of the resulting extracts. 
All of the extract preparation and SF2 purification procedures 
were performed at 0-4~ unless otherwise noted. All buffers 
containing N-(2-hydroxyethyl)piperazine-N'-{2-ethanesulfonic 
acid) (HEPES) were prepared from a 1 M stock that was adjusted 
to pH 8.0 at 25~ with NaOH. Dithiothreitol (DTT) was added 
flesh from a 1 M stock, and phenylmethylsulfonyl fluoride 
(PMSF) was added fresh from a 20 mg/ml stock in ethanol. 
Frozen HeLa cells (2.4 x 10~o; 400 ml suspension from a 24- 
liter culture) were thawed rapidly at 30~ and spun at 2500 rpm 
in the H-6000A rotor for 20 min. The cell pellet was resus- 
pended in 250 ml of PBS plus 0.5 rnM MgC12 and spun, as above, 
for 10 rain. The supematant was discarded and the packed cell 
volume noted. The cells were resuspended in an equal volume 
of buffer 1 [10 mM HEPES (pH 8.0), 10 mM KC1, 1.5 m~ MgCI2, 
and 0.5 mM DTT] and incubated for 10 min on ice. The cells 
were lysed in several batches in a 40-ml Dounce homogenizer 
with a B pestle (Kontes) and examined by phase-contrast mi- 
croscopy for cell lysis. When >90% lysis was achieved, the nu- 
clei were recovered by centrifugation at 2000 rpm (1164gm~ ) in 
the H-6000A rotor for 10 rain. The cytoplasmic fraction was 
removed, and the nuclei were pelleted in a Sorvall SS34 rotor 
for 20 rain at 16,500 rpm (32,530gm~). The supernatant was 
discarded and the packed nuclear volume noted. The nuclei 
were resuspended in an equal volume of buffer 2 [20 rnM HEPES 
(pH 8.0), 25% (vol/vol) glycerol, 0.42 M NaC1, 1.5 mM MgC12, 
0.2 rnM ethylenediaminetetraacetic acid (EDTA), 0.5 mM DTT, 
0.5 mM PMSF] by 10 strokes of a B pestle in a 40-ml Dounce 
homogenizer. The nuclear suspension was kept in ice water and 
sonicated in four 10-see bursts at 1-min intervals with a 
Branson sonifier with a l/2-inch disruptor horn. The complete 
disruption of nuclei was verified by microscopy. The homoge- 
nate was rocked for 30 min and spun at 16,500 rpm in the SS34 
rotor for 30 min to remove chromatin fragments and nucleoli. 
The supernatant was transferred to a clean tube, and the pellet 
was resuspended in an equal volume of buffer 2 containing only 
0.21 M NaC1, spun at 16,500 rpm for 20 min, and pooled with 
the previous upematant. The resulting extract was dialyzed 
overnight against 50 volumes of buffer 3 [20 mM HEPES (pH 
8.0), 0.1 M KC1, 5% (vol/vol) glycerol, 0.2 mM EDTA, and 1 mart 
DTT] containing 0.5 haM PMSF. The dialysate was spun at 
16,500 rpm in the SS34 rotor for 20 min to remove insoluble 
material. The dialysis step was omitted occasionally, but this 
often led to diminished solubility of SF2 in subsequent s eps. 
Purification of SF2 
The sonicated nuclear extract was diluted with 1.5 volumes of 
buffer 4 [20 mM HEPES (pH 8.0), 0.2 mM EDTA, 1 mM DTT]. To 
the resulting solution, an equal volume of saturated (NH4)2SO 4
in buffer 4 was added slowly with gentle stirring. [Saturated 
{NH4)2SO 4 (at 0~ was prepared by adding 69.7 g to each 100 
ml of buffer 4]. The 50% saturated suspension was stirred for 1 
hr and spun at 4000 rpm (4657gm~,) in the H-6000A rotor for 30 
min. The volume of the supematant was measured, and the 
(NH4)2SO 4concentration brought o 80% saturation (at 0~ by 
the addition of 19.4 g of solid (NH4)2SO 4per 100 ml of supema- 
tant. The suspension was gently stirred for 1 hr and spun as 
above. The supematant was discarded, and the 50-80% pellet 
was resuspended gently in buffer 3 in a final volume of 4 ml. 
This fraction contained the SF2 activity and only -10% of the 
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total protein and nucleic acid. This first step also removed a
great deal of particulate material, and essentially all detectable 
U snRNAs. 
The (NH4)2SO 4 fraction was applied to a 200-ml Sephacryl 
S200-HR (Pharmacia-LKB) column (100 x 1.6 cm) pre-equili- 
brated in buffer 3, and eluted at 0.5 ml/min. Five-milliliter f ac- 
tions were collected. The majority of SF2 activity eluted in the 
first two fractions after the void volume of this column, which 
has an exclusion limit for globular proteins of 200 kD. The 
highly reproducible behavior of SF2 on this column may reflect 
artifactual aggregation, the formation or maintenance of spe- 
cific protein or nucleoprotein complexes, or a possible particu- 
late nature. Because asmall amount of hnRNA copurified with 
SF2 through subsequent s eps and because SF2 can bind RNA, 
we favor the notion that, at this stage, SF2 is present as a ribo- 
nucleoprotein complex. The relative native molecular weight 
of SF2 later in the purification is -30 kD, as determined by gel 
filtration on Superose 12. 
The Sephacryl $200 HR peak fractions were pooled and ap- 
plied to a 1-ml Mono Q column (Pharmacia-LKB) pre-equil- 
ibrated in buffer 3, at a flow rate of 0.5 ml/min; 0.5-ml fractions 
were collected. The column was washed with 5 ml of buffer 3 
and subsequently eluted with 5 ml of buffer 3 containing 0.35 M 
KC1, followed by 5 ml of buffer 3 containing 1 M KC1 (or a 20-ml 
gradient of 0.35-1 M KC1 in buffer 3). SF2 bound very tightly to 
Mono Q and was recovered efficiently in the 0.35-1 M salt step. 
When a salt gradient was employed instead of a step gradient, 
SF2 activity trailed in a broad range of salt concentration, 
whereas most polypeptides eluted as sharp peaks (data not 
shown). This chromatographic behavior suggests that SF2 binds 
to Mono Q indirectly, via its interactions with high-molecular- 
weight RNA which, in turn, binds very tightly to anion ex- 
changers. 
The Mono Q fractions containing the protein peak were 
pooled (2 ml) and diluted with buffer 3 lacking KC1 and con- 
taining 3.4 M (NH4)2SO4 to a final concentration of 1.7 M 
(NH4)2SO4 (2 M in the experiment shown in Fig. 7). This solu- 
tion was applied to a 1-ml Phenyl-Superose column (Phar- 
macia-LKB) pre-equilibrated in buffer 3 lacking KC1 and 
containing 1.7 M (or 2 M) (NH4)2SO4, at a flow rate of 0.4 ml/ 
min. The column was washed with 1 ml of the same buffer and 
eluted with a 25-ml gradient of this buffer, in which the 
(NH4)2SO4 concentration decreased from 1.7 M (or 2 M) tO 0, 
while l-ml fractions were collected. SF2 activity emerged 
shortly after the gradient was started. The active fractions were 
pooled, dialyzed against buffer 3, and frozen in liquid nitrogen. 
Aliquots stored at - 70~ remained active for several months. 
Assays 
The preparation of splicing extracts, pre-mRNA substrates, and 
the splicing reaction conditions, RNA extraction, and assays 
have been described (Krainer et al. 1984; Ruskin et al. 1984; 
Krainer and Maniatis 1985). The human B-globin pre-mRNA 
substrate is a BamHI runoff 497-nucleotide SP6 transcript con- 
taining a 158-nucleotide first exon, a 209-nucleotide s cond 
exon, and a 130-nucleotide intact first intron. The spliced 
mRNA is 367 nucleotides. The HIV-1 pre-mRNA substrate is a 
525-nucleotide BamHI runoff SP6 transcript containing a 264- 
nucleotide first exon, a 108-nucleotide s cond exon, and a 153- 
nucleotide intron. The spliced mRNA is 372 nucleotides. The 
template was constructed by the subcloning of a 2.7-kb Hin- 
dIII-BamHI fragment from the plasmid PBC12/RSV/t23 
{Cullen 1986) into the corresponding sites in pSP64 (Melton et 
al. 1984). This fragment contains the two coding exons of the 
tat gene between the SalI (+ 5368) and BamHI (+ 8054) sites, 
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and a 2330-bp intron (Muesing et al. 1985). Internal intron se- 
quences between an SspI site (+5738) and an RsaI site ( + 7916) 
were deleted to generate a 153-nucleotide truncated intron. 
Nuclear and cytoplasmic S100 extracts (Dignam et al. 1983; 
Krainer et al. 1984) were dialyzed against buffer containing 5% 
instead of 20% glycerol. Micrococcal nuclease treatment and 
subsequent inactivation with ethylene glycol-bis(B-aminoethyl 
ether)N,N,N',N'-tetraacetic ac d (EGTA) were as described pre- 
viously (Krainer and Maniatis 1985). NEM (Fluka) treatments 
were performed on ice for 15 min in the presence of 10 m~ 
NEM, followed by addition of DTT to 20 raM. As a control, 
NEM and DTT were premixed prior to the addition of SF2. Pa- 
pain (Boehringer 1 treatments were done at 40 ~g/ml for 15 min 
at 30~ followed by inactivation with 10 lxg/ml E-64 
(Boehringer). As a control, the protease was inactivated with 
E-64 prior to the addition of SF2. 
Complementation reactions were carried out for 2-4 hr with 
7.5 ~1 of S100 extract and 1-7.5 Ixl of the appropriate protein 
fraction diluted to 7.5 ~1 with buffer 3 under otherwise standard 
splicing conditions {Krainer et al. 1984). Because splicing is 
highly sensitive to monovalent cation concentration (Krainer et 
al. 1984), small aliquots of the ammonium sulfate, Mono Q, 
and Phenyl-Superose fractions were dialyzed against buffer 3 
prior to the assaying for SF2 activity. Protein concentrations 
were determined by the method of Bradford (1976), with BSA as 
a standard. Protein gels were run according to Laemmli (1970). 
Staining was with Coomassie Blue K-250 or by the ammoniacal 
silver method of Wray et al. (1981). 
UV cross-linking Purified SF2 (6 ~1, phenyl-Superose fraction 
9) or 1.2 ~g nuclease-free bovine serum albumin in 6 ~t of 
buffer 3 was incubated with l0 S cpm of globin pre-mRNA or 
mRNA, labeled with all four a2p rNTPs to asp. act. of 1.6 x 10 z 
cpm/}xg, in a 10-txl reaction containing 3.2 mM MgCI~, for 15 
rain at 30~ The samples were then spotted on parafilm and 
irradiated with 254-nm light at 2 mW/cm 2 for 10 rain at room 
temperature. The samples were added to 10 tzl of 2 mg/ml 
RNase A and incubated for 15 min at 30~ They were then 
fractionated on a 12% SDS-polyacrylamide g l (Laemmli 1970). 
The gel was stained with Coomassie Blue R-250, destained, and 
autoradiographed. 
RNA annealing The substrates in the annealing/helicase 
assays were a 212-nucleotide sense fragment of human [3-globin 
transcribed from SP64-HI3A6 (Krainer et al. 1984), truncated 
with NspI, and a 518-nucleotide antisense fragment transcribed 
from SP65-anti-H[3, truncated with HindIII. This plasmid con- 
tains the HindIII-BamHI globin fragment from SP64-H~A6 
subcloned into the corresponding sites in pSP65 (Melton et al. 
1984). The transcripts were synthesized in the absence of a cap 
dinucleotide. The complementarity between the two RNAs is 
204 bp, and Tl-resistant fragments of 211 nucleotides are ex- 
pected based on the sequence (Lawn et al. 1980). The 25-1zl reac- 
tions contained 15 ~1 of buffer 3, including 3 ~1 of purified SF2 
or hnRNP A1 protein (1-5 vgl, 3.2 nan MgC12, 70 fmoles of 
each RNA and, in some cases, 0.5 mM ATP. The individual 
RNAs were either added separately to the reaction, or in some 
cases, they were first annealed by heating at 85~ for 3 min, 
followed by slow cooling to room temperature. Incubation in 
the presence of protein was for 30 min at 30~ after which 0.1 
unit of RNase T1 was added and allowed to digest he RNA for 
an additional 15 min at the same temperature. The RNAs were 
recovered by phenol extraction a d ethanol precipitation and 
were analyzed on a 5% polyacrylamide/urea gel. 
Spliceosorne assembly Electrophoretic analysis of spliceo- 
some complexes was carried out as described (Zillman et al. 
Splicing factor SF2 
1988), with BamHI runoff [3-globin pre-mRNA and the appro- 
priate extracts and fractions. 
Immunoprecipitation Approximately 10 ~g of purified SF2 
(phenyl-Superose fraction 9) was used to immunize rabbits ub- 
cutaneously on days 1, 10, 22, and 35. Ten microliters of preim- 
mune (day 0) or immune {day 43) sera were incubated with 10 
~1 of protein A-trisacryl beads (Pierce) in 0.5 ml of 20 mM 
HEPES (pH 8), 150 mM NaC1, and 0.05% Triton X-100 and 
washed four times with 1 ml of the same buffer. The immobi- 
lized IgG was incubated for 1 hr at 4~ with 60 ~1 of crude 
nuclear extract prepared from HeLa cells labeled with [aSS]me- 
thionine and cysteine. Labeling and extract preparation were as 
described (Conway et al. 1989). After four washes, as above, the 
immunoprecipitates were extracted by boiling in 50-~1 of 
sample loading buffer and analyzed by SDS-PAGE and fluorog- 
raphy (Laemmli 1970). 
RNP fractions snRNPs were purified by immunoaffinity chro- 
matography as described (Krainer 19881. hnRNP was a kind gift 
from W. LeStourgeon. 
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